Login / Signup

Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort.

Akihito KawazoeNoboru YamamotoNaotoshi SugimotoHiasto KawakamiTakashi OshimaKensei YamaguchiKaori HinoMotohiro HiraoYukinori KurokawaTakeshi KawakamiMasahiro TsudaHiroki HaraShota KanameDaiko MatsuokaYohei OtakeKeisuke YasudaTakao TakaseShuya TakashimaTaro SembaKei Muro
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Promising antitumor activity was observed with E7389-LF in combination with nivolumab in patients with gastric cancer, and no new safety signals were observed, compared with either monotherapy.
Keyphrases
  • phase ii study
  • open label
  • locally advanced
  • phase ii
  • drug delivery
  • clinical trial
  • metastatic breast cancer
  • combination therapy
  • squamous cell carcinoma
  • placebo controlled
  • phase iii
  • rectal cancer